文献速递类风湿关节炎

miR-124上调剂ABX464(obefazimod,每日50和100 mg)在活动性类风湿关节炎且对甲氨蝶呤和/或抗TNFα治疗反应不佳患者中的安全性和有效性:一项安慰剂对照II期研究

Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study.
PubMed 文献 · Ann Rheum Dis · 2022-07-12

这项2a期随机双盲安慰剂对照平行组研究在60例对甲氨蝶呤和/或抗TNFα治疗反应不佳的中重度活动性类风湿关节炎患者中评估ABX464联合甲氨蝶呤的安全性和有效性。ABX464 50 mg安全且耐受良好,第12周ACR20和ACR50应答率显著高于安慰剂;100 mg组因轻中度胃肠道不良事件导致高脱落率。作者认为50 mg每日或更低剂量值得探索。

要点

  • ABX464 50 mg安全且耐受良好,100 mg组因胃肠道不良事件脱落率高(9例)。
  • 第12周ABX464 50 mg的ACR20和ACR50应答率显著高于安慰剂。
  • 每个接受ABX464治疗的患者血液中miR-124均显著上调。

核心结论

  • ABX464 50 mg安全、耐受良好且显示出有前景的疗效。
  • 轻中度胃肠道不良事件导致ABX464 100 mg组患者高脱落率,该剂量可能不是合适的使用剂量。
  • 这些发现值得探索ABX464每日50 mg或更低剂量用于治疗类风湿关节炎患者。

研究设计与样本

  • 这是一项2a期随机、双盲、安慰剂对照、平行组研究,60例患者按1:1:1比例分组。
  • 研究对象为对甲氨蝶呤和/或抗TNFα治疗反应不佳的中重度活动性类风湿关节炎患者,ABX464与甲氨蝶呤联合使用。
  • 主要终点为ABX464的安全性;有效性终点包括ACR20/50/70应答比例、DAS28、简化疾病活动评分、临床疾病活动评分、EULAR应答、DAS28低疾病活动度或缓解。

主要发现

  • ABX464 50 mg安全且耐受良好;报告2例严重不良事件(安慰剂组1例,ABX464 100 mg组1例)。
  • 11例患者因不良事件退出(100 mg组9例,50 mg组1例,安慰剂组1例),停药主要因胃肠道疾病。
  • 未报告机会性感染、恶性肿瘤或死亡病例。
  • 与安慰剂相比,ABX464 50 mg在第12周达到ACR20和ACR50应答的患者比例显著更高。
  • 第12周ABX464组DAS28-C反应蛋白(CRP)和DAS28-红细胞沉降率显著下降,DAS28-CRP分类应答率或CDAI缓解率显著升高;每个接受ABX464治疗的患者血液中miR-124均显著上调。

局限性

  • 轻中度胃肠道不良事件导致ABX464 100 mg组患者高脱落率,该剂量可能不是合适的使用剂量。
  • 这些发现值得探索ABX464每日50 mg或更低剂量用于治疗类风湿关节炎患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This phase 2a randomised, double blind, placebo controlled, parallel group study evaluated the safety and efficacy of a first-in-class drug candidate ABX464 (obefazimod, 50 mg and 100 mg per day), which upregulates the biogenesis of the mRNA inhibitor micro-RNA (miR)-124, in combination with methotrexate (MTX) in 60 patients (1:1:1 ratio) with moderate-to-severe active rheumatoid arthritis (RA) who have inadequate response to MTX or/and to an anti-tumour necrosis factor alpha (TNFα) therapy. METHODS: The primary end point was the safety of ABX464; efficacy endpoints included the proportion of patients achieving American College of Rheumatology (ACR)20/50/70 responses, disease activity scores (DAS) 28, simplified disease activity score, clinical disease activity score), European League Against Rheumatism response, DAS28 low disease activity or remission. RESULTS: ABX464 50 mg was safe and well tolerated. Two serious adverse events were reported (one on placebo group and one on ABX464 100 mg). Eleven patients were withdrawn for AEs (9 patients on 100 mg, 1 on 50 mg and 1 on placebo). Drug discontinuation was mainly due to gastrointestinal disorders. No cases of opportunistic infection, no malignancies and no death were reported. Compared with placebo, ABX464 50 mg showed significantly higher proportions of patients achieving ACR20 and ACR50 responses at week 12. DAS28-C reactive protein (CRP) and DAS28-erythrocyte sedimentation rate decreased significantly and rates of categorical DAS28-CRP response or CDAI remission increased significantly on ABX464 at week 12. A significant upregulation of miR-124 was observed in blood for every patient dosed with ABX464. CONCLUSION: ABX464 50 mg was safe, well tolerated and showed a promising efficacy. Mild-to-moderate gastrointestinal AEs led to a high drop-out rate of patients on ABX464 100 mg, which may not be a relevant dose to use. These findings warrant exploration of ABX464 at 50 mg per day or less for treating patients with RA. TRIAL REGISTRATION NAME: Phase IIa randomised, double blind, placebo controlled, parallel group, multiple dose study on ABX464 in combination with MTX, in patients with moderate to severe active RA who have inadequate response to MTX or/and to an anti- TNFα therapy or intolerance to anti-TNFα therapy.EUDRACT number: 2018-004677-27 TRIAL REGISTRATION NUMBER: NCT03813199.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Daien C, Krogulec M, Gineste P, et al. Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study. Ann Rheum Dis. 2022. PMID: 35641124. doi:10.1136/annrheumdis-2022-222228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。